SEC Company Response from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Feb 27, 2012
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Feb. 27, 2012 · CIK: 0001137883 · Accession: 0001144204-12-011024
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-179331
Referenced dates: February 14, 2012
Letter
Securities and Exchange Commission (Mail Stop 4561) Registration Statement on Form S-1 Filed February 3, 2012 File No. 333-179331
Re: Brainstorm Cell Therapeutics Inc.
Dear Mr. Riedler:
We are in receipt of the letter dated February 14, 2012 from the Staff of the U.S. Securities and Exchange Commission containing comments on our above-captioned filing (the “Comment Letter”).
We are currently finalizing our audit of our financial statements for the year ended December 31, 2011. We anticipate that we can file an amendment to our S-1 Registration Statement which will include these audited financial statements the week of March 12th. We hereby request an extension for submitting a response to the Comment Letter. With such amendment, we will file a response letter to the Comment Letter and amend the S-1 accordingly.
If you have any questions with regards to this request please contact the undersigned at +972 3 923 6384 or Thomas Rosedale of BRL Law Group LLC at (617) 399-6935.
Very truly yours,
/s/ Liat
Sossover
Show Raw Text
CORRESP
1
filename1.htm
February 27, 2012
Jeffrey P. Riedler
Assistant Director
Securities and Exchange Commission (Mail Stop 4561)
100 F Street, N.E.
Washington, D.C. 20549
Re:
Brainstorm Cell Therapeutics Inc.
Registration Statement on Form S-1
Filed February 3, 2012
File No. 333-179331
Dear Mr. Riedler:
We are in receipt of the letter dated February
14, 2012 from the Staff of the U.S. Securities and Exchange Commission containing comments on our above-captioned filing (the “Comment
Letter”).
We are currently finalizing our audit of our
financial statements for the year ended December 31, 2011. We anticipate that we can file an amendment to our S-1 Registration
Statement which will include these audited financial statements the week of March 12th. We hereby request an extension for submitting
a response to the Comment Letter. With such amendment, we will file a response letter to the Comment Letter and amend the S-1 accordingly.
If you have any questions with regards to this
request please contact the undersigned at +972 3 923 6384 or Thomas Rosedale of BRL Law Group LLC at (617) 399-6935.
Very truly yours,
/s/ Liat
Sossover
Liat Sossover
Copy to: Thomas B. Rosedale, Esq.
BrainStorm Cell Therapeutics
Inc.
605 Third Avenue, 34th Floor
New York NY 10158
Tel: (646) 666 3188
BrainStorm
Cell Therapeutics Ltd.
12 Bazel St., POB 10019 Kiryat Aryeh,
Petach Tikva, Israel 49001
Tel: (972) 3.923.6384
Fax: (212) 286-1884
E-mail: info@brainstorm-cell.com